Wednesday, November 13, 2013, 9:00 a.m. - 10:55 a.m
Organized by NewSummit Biopharma

This panel will explore the current state of international multi-center clinical trials in China as well as policy support for drugs originally developed in China. Specifically, this conversation will reference translational and evidence-based medicine supported by the “national project” and its use of third-party evaluations. Panelists will delve into the issue of post-market evaluations and their role in improving the standardization of clinical medicine. Determining international standards in China for multi-center clinical trials and how to accelerate the process of overseas R&D efforts will serve as core themes throughout the discussion.

Panelists:

• Wen Aidong, Director, Drug Clinical Trial Department, the Fourth Military Medical University

First Affiliated Hospital

• Chen Biao, Director, Beijing Xuanwu Hospital

• Li Qing, Director, Development Center for Medical Science and Technology, Ministry of Health

• Wang Xin, Chairman, Beijing Bionovo

• Huang Yangbin, Chief Technology Officer, Shanghai Newsummit Biopharma Group